Navigation Links
NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults
Date:11/30/2009

ROCKVILLE, Md., Nov. 30 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today it has completed enrollment in the Phase II clinical study of its trivalent seasonal influenza (2008/2009 recommended strains) VLP vaccine candidate in healthy adults 60 years of age or older (older adults). This randomized, double-blind, active-controlled study is comparing the safety, tolerability and immunogenicity of two different doses (15 mcg and 60 mcg) of Novavax's trivalent seasonal influenza VLP vaccine to a commercially available trivalent inactivated vaccine, TIV (Fluzone®).

This study enrolled 467 older adults in a three-arm study at six different sites located within the United States. In addition to evaluating hemagglutinin inhibition (HAI) responses, anti-neuraminidase and cell-mediated immune responses are also being examined. Previous studies have shown that VLP-based flu vaccines drive strong neuraminidase inhibition (NAI) antibody titers and T-cell responses, indicating the potential for broader immunologic responses particularly in older adults.

"With the rapid completion of enrollment in this clinical trial as well as the first part of our H1N1 vaccine study in Mexico announced previously, we are on track to report results from our two most advanced clinical programs during the first quarter of next year," said Dr. Rahul Singhvi, President and Chief Executive Officer of Novavax. "If results from the seasonal flu vaccine study are positive, we will be able to advance this program into Phase III clinical testing as early as 2010."

Seasonal Influenza

Seasonal influenza infects between 5 percent and 20 percent of the world's population and kills between 250,000 and 500,000 people each year. In the United States, the Centers for Disease Control and Prevention estimates th
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Novavax Prices Public Offering of Common Stock
2. NOVAVAX Completes First Stage of Enrollment in Pivotal H1N1 Influenza Vaccine Study in the Country of Mexico
3. Novavax Announces Release Date of 2009 Third Quarter Financial Results and Investor Conference Call
4. NOVAVAX to Present at Oppenheimer 20th Annual Healthcare Conference
5. Novavax Announces Poster Presentation at the 47th Annual Meeting of the IDSA
6. Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India
7. Novavax Awarded NIH Grant for Respiratory Syncytial Virus (RSV) Vaccine Program
8. Novavax CEO to Present at the World Vaccine Congress 2009, Lyon, France
9. Novavax Announces Board of Director Changes
10. NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine Candidate
11. NOVAVAX Virus-Like Particle Vaccine Protects Against 2009 Pandemic H1N1 Influenza Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... Express Diagnostics Int’l, Inc., manufacturer of ... it has received Class III medical device license approval ... DrugCheck® NxStep Onsite Drug Screen Cup in Canada. ... device in near-patient settings, such as physicians’ offices. , ... Canada Class III approval for 24 different drugs and ...
(Date:6/18/2013)... In support of Swiss contributions to scientific ... Switzerland in New York is pleased to welcome the ... , to Manhattan. PlanetSolar is in New York ... with scientists on board from the University of Geneva. ... on energy from the sun and eliminates the need ...
(Date:6/18/2013)... DuPont welcomes 48 of the nation’s finest agricultural ... Teachers Ambassador Academy this week (NATAA) at the company’s ... , The NATAA “Ag Academy” is a professional development ... of the National FFA Foundation and the ... The highly recommended agriscience teachers, who are participating in ...
(Date:6/18/2013)... June 18, 2013 ... research firm, announces the initiation of full ... biopharmaceutical company developing and marketing products for ...      (Logo: http://photos.prnewswire.com/prnh/20130417/608168) ... examining the investment merits of BioAlliance Pharma, ...
Breaking Biology Technology:Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 3Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 2Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 3Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 4DuPont Sponsors National AgriScience Ambassador Academy 2DuPont Sponsors National AgriScience Ambassador Academy 3Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 2Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 3
... April 14, 2011 QRxPharma Limited (ASX: ... States Patent and Trademark Office (USPTO) issued the Company ... 2029. This patent covers a proprietary dosing algorithm for ... MoxDuo IR, thereby more effectively and safely managing acute ...
... Reportlinker.com announces that a new market ... Neurology Devices Market Outlook ... Interventional Neurology and Other ... Market Outlook in China to 2017 – ...
... COLUMBUS, Ohio Researchers here have created the ... with organic "spintronics" devices that utilize the ... data. Ezekiel Johnston-Halperin, assistant professor of physics, ... a unique plastic material that is under development ...
Cached Biology Technology:U.S. Patent and Trademark Office (USPTO) Issues QRxPharma a New Patent for MoxDuo® IR; Extends Patent Coverage to 2029 2U.S. Patent and Trademark Office (USPTO) Issues QRxPharma a New Patent for MoxDuo® IR; Extends Patent Coverage to 2029 3Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 2Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 3Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 4Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 5Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 6Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 7Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 8Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 9Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 10Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 11Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 12Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 13Researchers advance toward hybrid spintronic computer chips 2Researchers advance toward hybrid spintronic computer chips 3
(Date:6/18/2013)... Association for Molecular Pathology is proud to announce it ... Biology (FASEB) on July 1, 2013. The FASEB Board ... , The 26 constituent societies of FASEB represent ... for the advancement of research and education in biological ... more important now than ever," said Jennifer L. Hunt, ...
(Date:6/18/2013)... team of internationally recognized feline experts including veterinarians and ... University of Lincoln, U.K. and Dr Ilona Rodan, Director ... the International Society of Feline Medicine (ISFM) and the ... for veterinarians, owners and those working with cats on ... cat. The new guidelines appear in the Journal ...
(Date:6/17/2013)... Researchers have identified a new virus in patients with ... to determine whether the virus is responsible for the ... a total of 28 out of 644 patients with ... 4%, but not in any of the 122 patients ... of the brain and central nervous system are often ...
Breaking Biology News(10 mins):Feline behavior experts release guidelines to improve the welfare of cats 2New virus isolated from patients with severe brain infections 2New virus isolated from patients with severe brain infections 3
... from a clinical trial evaluating new drug combinations for ... aid agency Medecins Sans Frontieres (MSF), and its research ... Clinical Trials. , African trypanosomiasis, or sleeping sickness affects ... sub-Saharan Africa and is a serious disease for which ...
... managed by the antibody that's the workhorse of the ... bring together the phagosomes that corral invading pathogens and ... , The research, by Axel Nohturfft at Harvard University ... Massachusetts Institute of Technology, appears this week in the ...
... University of Pennsylvania’s School of Medicine have found by ... is possible to inhibit bone decay while simultaneously stimulating ... for osteoporosis and other bone diseases. Senior author Yongwon ... the University of Pennsylvania and colleagues report their findings ...
Cached Biology News:A key antibody, IgG, links cells' capture and disposal of germs 2'Best of both worlds' -- Targeting a single gene could inhibit bone decay and stimulate bone growth 2